Navigation Links
Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
Date:1/12/2009

MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of the Company's compound alagebrium. The study is designed to measure the effect of alagebrium on exercise tolerance in patients with chronic systolic heart failure. In addition, the Company anticipates completing enrollment of its BREAK (Beginning a Randomized Evaluation of the A.G.E. [Advanced Glycation End Product] Breaker Alagebrium in Diastolic Heart Failure) study in the First Quarter of 2009. BREAK, a randomized, double-blind, placebo controlled study, evaluates whether alagebrium (200mg twice daily) can improve exercise tolerance, as measured by the 6-minute walk test, in patients diagnosed with diastolic heart failure.

"We are extremely pleased with the progress thus far in our clinical program for alagebrium," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, developer of alagebrium. "Based on our dialogue with the FDA, we believe that exercise tolerance is an approvable regulatory endpoint, in patients with systolic or diastolic heart failure. Accordingly, we look forward to the timely completion of these studies which could provide proof of efficacy and a partial basis for drug approval."

About Alagebrium

Alagebrium is Synvista's clinical candidate for interfering with A.G.E.-related sclerosis and fibrosis of the heart, kidney and other tissues leading to heart failure, diabetic nephropathy and other disorders. It is a proprietary A.G.E. crosslink breaker that is designed to function unlike any previously developed pharmaceutical agents to reverse the disease states associated with age or diabetes-related stiffening of vessels, tissues and organs. Alagebrium has completed a series of
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  23andMe, Inc., the leading personal ... Lupus Research Study in collaboration with Pfizer Inc. ... lupus erythematosus, more commonly known as lupus, into the ... The effort is also in collaboration with the Lupus ... in May. Approximately 1.5 million people in ...
(Date:5/5/2015)... Plymouth, Mich. (PRWEB) May 05, 2015 ... expanding publishing services to develop custom course materials for ... with annual enrollments as low as 200 students. ... to a broader range of higher education instructors,” said ... around the country, we can do our part to ...
(Date:5/5/2015)... , May 5, 2015 Psyche Systems ... alliance which offers a first-of-its-kind platform that helps labs ... to lab results, transforms the way patients engage with ... Luminate Health provides a HIPAA-compliant digital platform ... access, manage, and understand their lab results, and uniquely ...
(Date:5/5/2015)... The Academy of Model Aeronautics is pleased ... Indiana Gov. Mike Pence, has declared August 15, 2015, ... a Family Fest and aviation themed Motorcycle Rally in ... Wounded Warrior Project. , National Model Aviation Day has ... foremost organization for model aviation—to celebrate the history of ...
Breaking Biology Technology:23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3State of Indiana proclaims August 15 as Model Aviation Day 2
... was the soccer-ball-shaped molecules dubbed buckyballs. Then it was ... in physics and nanotechnology is graphene: a remarkably ... rings much like molecular chicken wire. Not ... also is 10 times stronger than steel and it ...
... Conn., Nov. 17 Doctors Research Group, Inc. announced ... U.S. Food and Drug Administration (FDA) to market KRYPTONITE(TM) ... represents a major advancement in treating cranial defects due ... low exotherm cement and bone void filler approved for ...
... Nov. 17 Merriman Curhan Ford Group, Inc. (Nasdaq: ... (OTC Bulletin Board: PYMX) $20.7 million registered public offering of ... per unit, consist of one share of PolyMedix common stock ... share of PolyMedix common stock at $1.25 per share. , ...
Cached Biology Technology:New study confirms exotic electric properties of graphene 2New study confirms exotic electric properties of graphene 3Doctors Research Group Receives FDA Clearance for U.S. Distribution of KRYPTONITE(TM) Bone Cement 2Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... the Huntsman Cancer Institute at the University of Utah discovered ... to 30 percent of human tumors. , Called Ras, normal ... communication among cells. When mutated, however, Ras is an "oncogene" ... growth of cancers in the pancreas, colon and lung, as ...
... has shown that for some fish species, females prefer ... for mating. That does not exclude males with an ... the larger-endowed males in a predator-laden environment because they ... larger genitalia, who lose out because the size of ...
... world are breathing a sigh of relief, as ... harvested for their natural disease-fighting substances. Scientists recently ... symbiotically inside the sea squirt, actually produces the ... used in cancer treatment. , Despite decades of ...
Cached Biology News:Scientists inhibit cancer gene 2IMF Launches World’s First DNA Database for Myeloma Patients 2IMF Launches World’s First DNA Database for Myeloma Patients 3IMF Launches World’s First DNA Database for Myeloma Patients 4
... UNOsphere ion exchange media ... with high binding capacity. ... is a strong cation ... size of 120 micrometers. ...
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,487-9) or ... ID clarifier: centre neck 100 mm, ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Bio-Beads S-X media are neutral, ... size exclusion chromatography of lipophilic ... require organic eluents. The beads ... xylene, carbon tetrachloride, dimethylformamide, ketones, ...
Biology Products: